For the first time in a human trial, a class of drugs known as sodium-glucose cotransporter-2 (SGLT2) inhibitors, already known for their weight-loss and glucose-lowering benefits, has also been shown to reduce inflammatory cells in the blood known to cause cardiovascular disease. The findings were published in Circulation.